LinkedIn

 آمار

تعداد نشریات20
تعداد شماره‌ها1,089
تعداد مقالات9,995
تعداد مشاهده مقاله26,541,195
تعداد دریافت فایل اصل مقاله7,303,829
Jani Kargar Moghaddam, Saghi, Mohammadi Roushandeh, Amaneh, Hamidi, Masoud, Nemati, Shadman, Jahanian-Najafabadi, Ali, Habibi Roudkenar, Mehryar. (1402). Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker. سامانه مدیریت نشریات علمی, 48(3), 268-276. doi: 10.30476/ijms.2022.93041.2452
Saghi Jani Kargar Moghaddam; Amaneh Mohammadi Roushandeh; Masoud Hamidi; Shadman Nemati; Ali Jahanian-Najafabadi; Mehryar Habibi Roudkenar. "Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker". سامانه مدیریت نشریات علمی, 48, 3, 1402, 268-276. doi: 10.30476/ijms.2022.93041.2452
Jani Kargar Moghaddam, Saghi, Mohammadi Roushandeh, Amaneh, Hamidi, Masoud, Nemati, Shadman, Jahanian-Najafabadi, Ali, Habibi Roudkenar, Mehryar. (1402). 'Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker', سامانه مدیریت نشریات علمی, 48(3), pp. 268-276. doi: 10.30476/ijms.2022.93041.2452
Jani Kargar Moghaddam, Saghi, Mohammadi Roushandeh, Amaneh, Hamidi, Masoud, Nemati, Shadman, Jahanian-Najafabadi, Ali, Habibi Roudkenar, Mehryar. Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker. سامانه مدیریت نشریات علمی, 1402; 48(3): 268-276. doi: 10.30476/ijms.2022.93041.2452

Lipocalin-2 Upregulation in Nasopharyngeal Carcinoma: A Novel Potential Diagnostic Biomarker

Iranian Journal of Medical Sciences
مقاله 4، دوره 48، شماره 3، مرداد 2023، صفحه 268-276    اصل مقاله (2.07 M)
نوع مقاله: Original Article(s)
شناسه دیجیتال (DOI): 10.30476/ijms.2022.93041.2452
نویسندگان
Saghi Jani Kargar Moghaddam1؛ Amaneh Mohammadi Roushandeh1، 2؛ Masoud Hamidi1؛ Shadman Nemati3؛ Ali Jahanian-Najafabadi4؛ Mehryar Habibi Roudkenar* 5
1Department of Medical Biotechnology, School of Paramedicine, Guilan University of Medical Sciences, Rasht, Iran
2Cellular and Molecular Research Center, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3Otorhinolaryngology Research Center, School of Medicine, Amiralmomenin Hospital, Guilan University of Medical Sciences, Rasht, Iran
4Department of Pharmaceutical Biotechnology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran
5Burn and Regenerative Medicine Research Center, Guilan University of Medical Sciences, Rasht, Iran
چکیده
Background: Lipocalin-2 (LCN2) deregulation has been reported in several types of cancer and is implicated in the proliferation, migration, angiogenesis, and progression of tumors. However, its aberrant expression has been rarely studied in nasopharyngeal carcinoma (NPC). In the present study, we investigated the expression of LCN2 in NPC patients. 
Methods: In this descriptive cross-sectional study, 29 NPC and 20 non-cancerous control paraffin pathology blocks were obtained from the seven-year (2011 to 2018) archive of Razi Laboratory in Rasht, Iran. LCN2 mRNA expression was evaluated through quantitative real-time PCR. In addition, immunohistochemistry was performed to evaluate LCN2 expression at the protein level. The fold change value and total immunostaining score (TIS) were applied for quantitative evaluation. The nonparametric Mann-Whitney U test and Fisher’s exact test were used through GraphPad Prism 8.3.0 software. P<0.05 was considered statistically significant.
Results: Our results revealed that LCN2 mRNA and protein levels in NPC tissues were significantly higher than control tissues (P=0.028 and P=0.002, respectively). At the protein level, 65.51% (19/29) of NPC patients were categorized as having high LCN2 expression (TIS>3) and 34.47% (10/29) as low expression (TIS≤3). While in the control group, 25% (5/20) of subjects represented a high expression of LCN2 (TIS>3), and 75% (15/20) showed no or weak expression (TIS≤3). No significant correlation was found between the overexpression of LCN2 at the protein level and the demographic features of the patients. 
Conclusion: Our findings suggest that LCN2 might be considered a potential new diagnostic marker for NPC. However, this warrants further studies. 
کلیدواژه‌ها
Lipocalin-2؛ Nasopharyngeal carcinoma؛ Immunohistochemistry؛ Biomarkers؛ Head and neck neoplasms
سایر فایل های مرتبط با مقاله
مراجع
  1. Mahdavifar N, Towhidi F, Makhsosi BR, Pakzad R, Moini A, Ahmadi A, et al. Incidence and Mortality of Nasopharynx Cancer and Its Relationship With Human Development Index in the World in 2012. World J Oncol. 2016;7:109-18. doi: 10.14740/wjon980w. PubMed PMID: 28983375; PubMed Central PMCID: PMCPMC5624652.
  2. Noorlag R, van der Groep P, Leusink FK, van Hooff SR, Frank MH, Willems SM, et al. Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2. Head Neck. 2015;37:1130-6. doi: 10.1002/hed.23716. PubMed PMID: 24764155.
  3. Chang ET, Ye W, Zeng YX, Adami HO. The Evolving Epidemiology of Nasopharyngeal Carcinoma. Cancer Epidemiol Biomarkers Prev. 2021;30:1035-47. doi: 10.1158/1055-9965.EPI-20-1702. PubMed PMID: 33849968.
  4. Mahdavifar N, Ghoncheh M, Mohammadian-Hafshejani A, Khosravi B, Salehiniya H. Epidemiology and Inequality in the Incidence and Mortality of Nasopharynx Cancer in Asia. Osong Public Health Res Perspect. 2016;7:360-72. doi: 10.1016/j.phrp.2016.11.002. PubMed PMID: 28053841; PubMed Central PMCID: PMCPMC5194228.
  5. Lao TD, Le TAH. Epidemiology, incidence and mortality of Nasopharynx Cancer in Southeast Asia: an update report. Advancements in Life Sciences. 2020;7:86-90.
  6. Franchi A, Palomba A, El-Mofty SK. Nasopharynx and Oropharynx. In: Cardesa A, Slootweg PJ, Gale N, Franchi A, editors. Pathology of the Head and Neck. Berlin: Springer; 2016. p. 295-331. doi: 10.1007/978-3-662-49672-5_6.
  7. Tsao SW, Yip YL, Tsang CM, Pang PS, Lau VM, Zhang G, et al. Etiological factors of nasopharyngeal carcinoma. Oral Oncol. 2014;50:330-8. doi: 10.1016/j.oraloncology.2014.02.006. PubMed PMID: 24630258.
  8. Wang Y, Shen C, Lu X, Hu C. The incidence and prognosis of nasopharyngeal carcinoma patients with family history. Oncotarget. 2017;8:97323-30. doi: 10.18632/oncotarget.21994. PubMed PMID: 29228613; PubMed Central PMCID: PMCPMC5722565.
  9. Feng B-J. Descriptive, environmental and genetic epidemiology of nasopharyngeal carcinoma. Nasopharyngeal carcinoma: Springer; 2013. p. 23-41. doi: 10.1007/978-1-4614-5947-7_3.
  10. Chang ET, Liu Z, Hildesheim A, Liu Q, Cai Y, Zhang Z, et al. Active and Passive Smoking and Risk of Nasopharyngeal Carcinoma: A Population-Based Case-Control Study in Southern China. Am J Epidemiol. 2017;185:1272-80. doi: 10.1093/aje/kwx018. PubMed PMID: 28459936; PubMed Central PMCID: PMCPMC5860561.
  11. Xiao X, Zhang Z, Chang ET, Liu Z, Liu Q, Cai Y, et al. Medical History, Medication Use, and Risk of Nasopharyngeal Carcinoma. Am J Epidemiol. 2018;187:2117-25. doi: 10.1093/aje/kwy095. PubMed PMID: 29701753; PubMed Central PMCID: PMCPMC6166212.
  12. Roy Chattopadhyay N, Das P, Chatterjee K, Choudhuri T. Higher incidence of nasopharyngeal carcinoma in some regions in the world confers for interplay between genetic factors and external stimuli. Drug Discov Ther. 2017;11:170-80. doi: 10.5582/ddt.2017.01030. PubMed PMID: 28867748.
  13. Alotaibi AD, Ahmed HG, Elasbali AM. Nasopharyngeal cancer in Saudi Arabia: Epidemiology and possible risk factors. Journal of Oncological Sciences. 2019;5:23-30. doi: 10.1016/j.jons.2019.01.002.
  14. Chua MLK, Wee JTS, Hui EP, Chan ATC. Nasopharyngeal carcinoma. Lancet. 2016;387:1012-24. doi: 10.1016/S0140-6736(15)00055-0. PubMed PMID: 26321262.
  15. Schreiber AM, Dawson C, Skoretz SA. Late Dysphagia Following Radiotherapy After Nasopharyngeal Carcinoma: A Case Series. Am J Speech Lang Pathol. 2020;29:319-26. doi: 10.1044/2019_AJSLP-19-0116. PubMed PMID: 31805250.
  16. Wang C, Wang F, Min X, Zhang Q, Shen LJ, Jiang Y, et al. Toxicities of chemoradiotherapy and radiotherapy in nasopharyngeal carcinoma: an updated meta-analysis. J Int Med Res. 2019;47:2832-47. doi: 10.1177/0300060519858031. PubMed PMID: 31272262; PubMed Central PMCID: PMCPMC6683919.
  17. Hutajulu SH, Kurnianda J, Tan IB, Middeldorp JM. Therapeutic implications of Epstein-Barr virus infection for the treatment of nasopharyngeal carcinoma. Ther Clin Risk Manag. 2014;10:721-36. doi: 10.2147/TCRM.S47434. PubMed PMID: 25228810; PubMed Central PMCID: PMCPMC4161530.
  18. Balasubramanian A, Lazim NM. Nasopharyngeal carcinoma screening and prevention programs. An Evidence-Based Approach to the Management of Nasopharyngeal Cancer: Elsevier; 2020. p. 241-53.
  19. Yang S, Wu S, Zhou J, Chen XY. Screening for nasopharyngeal cancer. Cochrane Database Syst Rev. 2015;2015:CD008423. doi: 10.1002/14651858.CD008423.pub2. PubMed PMID: 26544798; PubMed Central PMCID: PMCPMC6486300.
  20. Monisha J, Roy NK, Padmavathi G, Banik K, Bordoloi D, Khwairakpam AD, et al. NGAL is Downregulated in Oral Squamous Cell Carcinoma and Leads to Increased Survival, Proliferation, Migration and Chemoresistance. Cancers (Basel). 2018;10. doi: 10.3390/cancers10070228. PubMed PMID: 29996471; PubMed Central PMCID: PMCPMC6071146.
  21. Rahimi S, Roushandeh AM, Ahmadzadeh E, Jahanian-Najafabadi A, Roudkenar MH. Implication and role of neutrophil gelatinase-associated lipocalin in cancer: lipocalin-2 as a potential novel emerging comprehensive therapeutic target for a variety of cancer types. Mol Biol Rep. 2020;47:2327-46. doi: 10.1007/s11033-020-05261-5. PubMed PMID: 31970626.
  22. Wargasetia TL, Priyandoko D. Upregulation of two human microRNAs which might be involved in the carcinogenesis of nasopharyngeal cancer and that are promising for biomarker development. Comparative Clinical Pathology. 2018;27:795-801. doi: 10.1007/s00580-018-2721-6.
  23. Feng Y, Zhang N, Wang S, Zou W, He Y, Ma JA, et al. Systemic Inflammation Response Index Is a Predictor of Poor Survival in Locally Advanced Nasopharyngeal Carcinoma: A Propensity Score Matching Study. Front Oncol. 2020;10:575417. doi: 10.3389/fonc.2020.575417. PubMed PMID: 33363009; PubMed Central PMCID: PMCPMC7759154.
  24. Song J, Kim OY. Perspectives in Lipocalin-2: Emerging Biomarker for Medical Diagnosis and Prognosis for Alzheimer’s Disease. Clin Nutr Res. 2018;7:1-10. doi: 10.7762/cnr.2018.7.1.1. PubMed PMID: 29423384; PubMed Central PMCID: PMCPMC5796918.
  25. Halabian R, Roudkenar MH, Jahanian-Najafabadi A, Hosseini KM, Tehrani HA. Co-culture of bone marrow-derived mesenchymal stem cells overexpressing lipocalin 2 with HK-2 and HEK293 cells protects the kidney cells against cisplatin-induced injury. Cell Biol Int. 2015;39:152-63. doi: 10.1002/cbin.10344. PubMed PMID: 25049146.
  26. Woo HJ, Min JK, Bai CH, Song SY, Kang HJ, Lee HM, et al. Expression of neutrophil gelatinase-associated lipocalin in nasal polyps. Arch Otolaryngol Head Neck Surg. 2008;134:1182-6. doi: 10.1001/archotol.134.11.1182. PubMed PMID: 19015448.
  27. Xu B, Jin DY, Lou WH, Wang DS. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. World J Surg. 2013;37:1892-900. doi: 10.1007/s00268-013-2009-6. PubMed PMID: 23539193.
  28. Oren B, Urosevic J, Mertens C, Mora J, Guiu M, Gomis RR, et al. Tumour stroma-derived lipocalin-2 promotes breast cancer metastasis. J Pathol. 2016;239:274-85. doi: 10.1002/path.4724. PubMed PMID: 27038000.
  29. Huang DY, Dai ZR, Li WM, Wang RG, Yang SM. Inhibition of EGF expression and NF-kappaB activity by treatment with quercetin leads to suppression of angiogenesis in nasopharyngeal carcinoma. Saudi J Biol Sci. 2018;25:826-31. doi: 10.1016/j.sjbs.2016.11.011. PubMed PMID: 29740251; PubMed Central PMCID: PMCPMC5936869.
  30. Sadeghi F, Etebari M, Habibi Roudkenar M, Jahanian-Najafabadi A. Lipocalin2 Protects Human Embryonic Kidney Cells against Cisplatin-Induced Genotoxicity. Iran J Pharm Res. 2018;17:147-54. PubMed PMID: 29755547; PubMed Central PMCID: PMCPMC5937086.
  31. Ding G, Fang J, Tong S, Qu L, Jiang H, Ding Q, et al. Over-expression of lipocalin 2 promotes cell migration and invasion through activating ERK signaling to increase SLUG expression in prostate cancer. Prostate. 2015;75:957-68. doi: 10.1002/pros.22978. PubMed PMID: 25728945.
  32. Guo Y, Zhai J, Zhang J, Zhou H. NGAL protects in nasopharyngeal carcinoma by inducing apoptosis and blocking epithelial-mesenchymal transition. Oncol Lett. 2020;19:3711-8. doi: 10.3892/ol.2020.11527. PubMed PMID: 32391093; PubMed Central PMCID: PMCPMC7204640.
  33. Miyamoto T, Asaka R, Suzuki A, Takatsu A, Kashima H, Shiozawa T. Immunohistochemical detection of a specific receptor for lipocalin2 (solute carrier family 22 member 17, SLC22A17) and its prognostic significance in endometrial carcinoma. Exp Mol Pathol. 2011;91:563-8. doi: 10.1016/j.yexmp.2011.06.002. PubMed PMID: 21763306.
  34. Zhang H, Xu L, Xiao D, Xie J, Zeng H, Wang Z, et al. Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol. 2007;60:555-61. doi: 10.1136/jcp.2006.039297. PubMed PMID: 17412867; PubMed Central PMCID: PMCPMC1994524.
  35. Barresi V, Ieni A, Bolignano D, Magno C, Buemi M, Barresi G. Neutrophil gelatinase-associated lipocalin immunoexpression in renal tumors: correlation with histotype and histological grade. Oncol Rep. 2010;24:305-10. doi: 10.3892/or_00000860. PubMed PMID: 20596614.
  36. Schröder S, Asimakopoulou A, Weiskirchen R. Lipocalin 2 as a potential diagnostic and/or prognostic biomarker in prostate, lung and liver cancer. Clin Oncol. 2018;1:1-14.
  37. Zhang Y, Fan Y, Mei Z. NGAL and NGALR overexpression in human hepatocellular carcinoma toward a molecular prognostic classification. Cancer Epidemiol. 2012;36:e294-9. doi: 10.1016/j.canep.2012.05.012. PubMed PMID: 22728279.
  38. Magdeldin S, Yamamoto T. Toward deciphering proteomes of formalin-fixed paraffin-embedded (FFPE) tissues. Proteomics. 2012;12:1045-58. doi: 10.1002/pmic.201100550. PubMed PMID: 22318899; PubMed Central PMCID: PMCPMC3561704.
  39. Tabola R, Zaremba-Czogalla M, Baczynska D, Cirocchi R, Stach K, Grabowski K, et al. Fibroblast activating protein-alpha expression in squamous cell carcinoma of the esophagus in primary and irradiated tumors: the use of archival FFPE material for molecular techniques. Eur J Histochem. 2017;61:2793. doi: 10.4081/ejh.2017.2793. PubMed PMID: 28735527; PubMed Central PMCID: PMCPMC5484010.
  40. Bass BP, Engel KB, Greytak SR, Moore HM. A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med. 2014;138:1520-30. doi: 10.5858/arpa.2013-0691-RA. PubMed PMID: 25357115.
آمار
تعداد مشاهده مقاله: 529
تعداد دریافت فایل اصل مقاله: 438


سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب